Mutational Landscape of Ameloblastoma: Analysis of BRAF and Other Key Mutations in Chinese Patients
Oral Diseases · 2025-07 · 31 (7) · 2215-2220
DOI: 10.1111/odi.15286 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 03.03.2025. Verfasst von Zhu You und 7 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Or…. Hauptthemen laut MEDLINE: Ameloblastoma, Proto-Oncogene Proteins B-raf, Mutation, Mandibular Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
To investigate the prevalence of BRAF , SMO , KRAS , HRAS , NRAS , FGRF2 , and CTNNB1 gene mutations in Chinese ameloblastoma (AM) patients and explore their associations with clinical characteristics. Materials and Methods DNA was extracted from 89 formalin‐fixed paraffin‐embedded AM samples (9 unicystic and 80 conventional). PCR and Sanger sequencing were used to detect mutations, followed by statistical analysis to assess correlations between mutations and clinical variables.
Results
BRAF V600E mutations were significantly prevalent, occurring in 92% (59/64) of mandibular AMs compared to 40% (10/25) in maxillary AMs. SMO mutations were found in 20% (5/25) of maxillary and 3.1% (2/64) of mandibular AMs. FGFR2 mutations were detected in six maxillary and two mandibular AMs, while RAS mutations were present in four maxillary and one mandibular AM. No detectable HRAS , NRAS(G12) , or CTNNB1 mutations were observed. BRAF mutations showed mutual exclusivity with SMO and FGFR2 mutations.
Conclusion
The high prevalence of BRAF V600E mutations, particularly in mandibular AMs, suggests its potential as a diagnostic and therapeutic target. Distinct mutation profiles between maxillary and mandibular AMs indicate molecular diversity. In BRAF ‐negative cases, alternative oncogenic pathways involving SMO , FGFR2 , and RAS may be actionable targets, underscoring the need for personalized treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Laboratory, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterial…
- Department of Oral and Maxillofacial Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- First Dental Center, School and Hospital of Stomatology, Peking University School and Hospital of Stomatology, Beijing, China.
- Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China.
ORCID-Profile: Lisha Sun
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
Zitieren
APA
You, Z., Sima, Z., Guo, X., Li, X., Feng, Y., Du, N., Zhang, H., & Sun, L. (2025). Mutational Landscape of Ameloblastoma: Analysis of BRAF and Other Key Mutations in Chinese Patients. Oral Diseases, 31(7), 2215-2220. https://doi.org/10.1111/odi.15286
Vancouver
You Z, Sima Z, Guo X, Li X, Feng Y, Du N, et al. Mutational Landscape of Ameloblastoma: Analysis of BRAF and Other Key Mutations in Chinese Patients. Oral Diseases. 2025;31(7):2215-2220. doi:10.1111/odi.15286
BibTeX
@article{You2025,
author = {You, Zhu and Sima, Zihan and Guo, Xiaowen and Li, Xuefen and Feng, Yanrui and Du, Ning and Zhang, Heyu and Sun, Lisha},
title = {Mutational Landscape of Ameloblastoma: Analysis of BRAF and Other Key Mutations in Chinese Patients},
journal = {Oral Diseases},
year = {2025},
volume = {31},
number = {7},
pages = {2215--2220},
doi = {10.1111/odi.15286}
}
EUVIMED